Structure via PubChem · Public domain (PubChem)
paritaprevir
Sign in to saveAlso known as Veruprevir, ABT450, ABT 450
Paritaprevir (previously known as ABT-450) is an acylsulfonamide inhibitor of the NS3-4A serine protease manufactured by Abbott Laboratories that shows promising results as a treatment of hepatitis C. When given in combination with ritonavir and ribavirin for 12 weeks, the rate of sustained virologic response at 24 weeks after treatment has been estimated to be 95% for those with hepatitis C virus genotype 1. Resistance to treatment with paritaprevir is uncommon, because it targets the binding site, but has been seen to arise due to mutations at positions 155 and 168 in NS3.
Key facts
- Drug.IUPAC_name
- (2R,6S,12Z,13aS,14aR,16aS)-N-(Cyclopropylsulfonyl)-6-{[(5-methyl-2-pyrazinyl)carbonyl]amino}-5,16-dioxo-2-(6-phenanthridinyloxy)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo [1,2-a] [1,4]diazacyclopentadecine-14a(5H)-carboxamide
- Drug.image
- File:Paritaprevir structure 2.svg
- Drug.width
- 285
- Drug.tradename
- Viekira Pak (in combination with ombitasvir, ritonavir and dasabuvir), Technivie/Viekirax (in combination with ombitasvir and ritonavir)
- Drug.pregnancy_US
- B
- Drug.licence_EU
- yes
- Drug.legal_US
- Rx-only
- Drug.routes_of_administration
- Oral
- Drug.bioavailability
- was not evaluated
- Drug.protein_bound
- 97–98.6%
- Drug.metabolism
- Hepatic, CYP3A4 and CYP3A5
- Drug.onset
- 4 to 5 hours
- Drug.elimination_half life
- 5.5 hours
- Drug.excretion
- feces (88%), urine (8,8%)
- Drug.CAS_number
- 1216941-48-8
- Drug.UNII
- OU2YM37K86
- Drug.ATC_prefix
- J05
- Drug.ATC_suffix
- AP52
via Wikipedia infobox
Chemical data
- Formula
- C40H43N7O7S
- Molecular weight
- 765.9 g/mol
- IUPAC name
- (1S,4R,6R,7Z,14S,18R)-N-cyclopropylsulfonyl-14-[(5-methylpyrazine-2-carbonyl)amino]-2,15-dioxo-18-phenanthridin-6-yloxy-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxamide
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2014
- Admin. routes
- oral
- Indications
- chronic hepatitis C virus infection, hepatitis C virus infection, hepatitis B virus infection
via ChEMBL · EBI
~3 min read
Encyclopedic overview
1 sectionsContents
- References
{{Infobox drug | drug_name = | IUPAC_name = (2R,6S,12Z,13aS,14aR,16aS)-N-(Cyclopropylsulfonyl)-6-{[(5-methyl-2-pyrazinyl)carbonyl]amino}-5,16-dioxo-2-(6-phenanthridinyloxy)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo [1,2-a] [1,4]diazacyclopentadecine-14a(5H)-carboxamide | image = File:Paritaprevir structure 2.svg | width = 285 | alt = | caption =
| tradename = Viekira Pak (in combination with ombitasvir, ritonavir and dasabuvir), Technivie/Viekirax (in combination with ombitasvir and ritonavir) | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = B | pregnancy_category = | licence_EU = yes | legal_AU = | legal_CA = | legal_UK = | legal_US = Rx-only | legal_status = | routes_of_administration = Oral
Excerpted from Wikipedia’s “paritaprevir” article, available under the CC BY-SA 4.0 licence.